ARGENICA THERAPEUTICS ORD
Argenica Study Confirms Compatibility of ARG-007 Candidate with Stroke Treatment Standard-of-Care Therapies
Argenica Therapeutics (ASX: AGN) has reported positive results from a drug-to-drug interaction assessment showing its lead candidate ARG-007 does not interfere with clot-dissolving agent tenecteplase in the treatment of acute ischemic stroke.
Argenica Therapeutics Validates Efficacious ARG-007 Dose in New Pre-Clinical Stroke Study
Argenica Therapeutics (ASX: AGN) has released new data from an independent pre-clinical study validating the efficacy and dosing of lead neuroprotective peptide candidate ARG-007 for ischaemic stroke.
Argenica Therapeutics Releases Positive Safety Data from Phase 2 ARG-007 Stroke Trial
Perth-based biotech Argenica Therapeutics (ASX: AGN) has released top-line safety results from its Phase 2 trial evaluating lead candidate ARG-007 on patients with acute ischaemic stroke (AIS) who are undergoing mechanical removal of a blood clot in the brain. The multi-centre, double-blind, randomised, placebo-controlled, single-dose clinical study conducted by the company’s clinical research organisation ProPharma […]
Argenica Therapeutics gains ethics approval for phase 1 clinical trial of stroke drug ARG-007
Perth-based biotechnology company Argenica Therapeutics (ASX: AGN) has gained ethics approval to commence a pivotal phase 1 clinical trial of lead drug ARG-007 in healthy participants. ARG-007 is being developed as a novel therapeutic to reduce brain tissue death after stroke with potential to enhance recovery once a stroke has taken place. Approval for the […]